Director Robert Willett recently sold 2,148 shares of Cognex (NASDAQ:CGNX) through an open-market transaction on February 13, 2026. This sale followed an immediate option exercise, as disclosed in the SEC Form 4 filing. The transaction was valued at approximately $128,000, based on a weighted average purchase price of $59.50 per share.
Despite selling all of his direct common stock holdings, Mr. Willett still maintains exposure to Cognex through 15,804 shares held indirectly via the Willett Parkhill Investment Trust, as well as a significant pool of 1,477,706 vested options that remain exercisable. This indicates that he retains a substantial interest in the company.
The sale represented 11.97% of Mr. Willett’s total holdings before the transaction, and 100% of his direct common stock position. However, with substantial indirect holdings and a large number of options, he has the capacity for future transactions, whether to increase or monetize his equity interests.
This transaction was a derivative-based event, involving the exercise of stock options followed by the sale of shares. It was part of Mr. Willett’s liquidity management practices rather than a reduction in his underlying economic exposure to Cognex.
Cognex is a leading provider of machine vision products used for automation and quality control in various manufacturing and distribution industries. The company’s advanced imaging and deep learning technologies enable high-precision inspection and identification solutions, positioning it competitively in the automation technology market.
The rise in Cognex’s stock price, reaching a 52-week high of $59.88 just before the sale, reflects the company’s strong performance. With revenue increasing by 9% year over year to $994 million in 2025, Cognex’s machine vision technology is in high demand, particularly for applications involving artificial intelligence.
While the stock’s price-to-earnings ratio exceeds 82, suggesting a lofty valuation, shareholders may consider waiting for a potential drop in the stock price before making any new purchases. It’s essential to weigh the current valuation against the company’s growth prospects and industry trends before investing in Cognex.
In conclusion, Robert Willett’s recent sale of Cognex shares does not raise any red flags, as it was part of his planned trading activity. With a significant number of options and indirect holdings, he remains invested in the company’s future success. Investors should consider the company’s financial performance and valuation metrics before making any investment decisions related to Cognex.
